Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Vumerity (Diroximel fumarate (BIIB098)) — Biogen Netherlands B.V.
EMA has authorised Vumerity (diroximel fumarate) for relapsing-remitting multiple sclerosis, expanding Biogen's portfolio in this indication…
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]
A Phase 3 study evaluating monthly long-acting GA Depot injections for efficacy, safety, and tolerability in relapsing-remitting multiple sc…
-
EMA approval · 2026-07-03EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited
Kesimpta (ofatumumab) has been authorised in the EU for Relapsing-Remitting Multiple Sclerosis.
-
EMA approval · 2026-06-11EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
Teriflunomide Viatris has been authorised in the EU for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) [Phase 3]
Phase 3 trial comparing ABP 692 against Ocrevus (ocrelizumab) for relapsing-remitting multiple sclerosis (RRMS).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis [Phase 1]
Phase 1 clinical trial evaluating peptide-coupled red blood cells for relapsing-remitting multiple sclerosis has completed with posted resul…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) [Phase 2]
A Phase 2 study to evaluate pharmacokinetics, safety, tolerability, immunogenicity and pharmacodynamic effects of subcutaneous ocrelizumab i…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study [NA]
A pilot clinical trial evaluating the SetPoint System as a pro-remyelination therapy for relapsing-remitting multiple sclerosis is currently…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
An exploratory trial on the timing of multiple sclerosis symptoms (NCT00919217) sponsored by the University of Louisville has been terminate…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial [Phase 2]
RC18 is being studied in relapsing-remitting multiple sclerosis in a Phase II trial. The study status is terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) [Phase 3]
Phase 3 clinical trial comparing ABP 692 to Ocrevus (ocrelizumab) in relapsing-remitting multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
This is an Italian multicenter, prospective observational study evaluating Ofatumumab in Relapsing-Remitting multiple sclerosis, sponsored b…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial is assessing the safety and efficacy of Extracorporeal Photopheresis for Multiple Sclerosis, including Relapsing-…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: The HIt HArd and hiT Early in Multiple Sclerosis Trial [Phase 2]
A Phase 2 clinical trial update for Relapsing-remitting multiple sclerosis led by Uppsala University, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Biogen-sponsored study leveraging EU MS registry data to assess the incidence of anti-natalizumab antibodies in relapsing-remitting multiple…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial to evaluate the safety and efficacy of fingolimod in Taiwanese adults with relapsing-remitting multiple sclerosis i…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Functional Outcomes From Diets in Multiple Sclerosis [NA]
This clinical trial update reports on functional outcomes from dietary interventions in people with relapsing-remitting multiple sclerosis a…
-
CLINICAL_TRIALS other · 2026-04-03Clinical Trial Update: Effects of Ocrevus in Relapsing Multiple Sclerosis [Phase 4]
This clinical trial update notes the Phase 4 study of Ocrevus (ocrelizumab) in relapsing-remitting multiple sclerosis, with status listed as…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis [Phase 2]
Phase 2 clinical trial update investigating hyperpolarized carbon metabolic imaging as a biomarker in multiple sclerosis, currently not yet …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation [Phase 4]
A Phase 4 multicenter study compares continuing current multiple sclerosis therapy versus transitioning to ofatumumab after elevated neurofi…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis
This ClinicalTrials.gov update outlines a study assessing the prevalence of malnutrition in patients with relapsing-remitting multiple scler…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis [Phase 4]
Phase 4 clinical trial update on ocrelizumab in relapsing-remitting multiple sclerosis, describing its effects on immune cells in lymph node…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis [NA]
A clinical trial update notes a study exploring OCT imaging biomarkers to evaluate Ublituximab treatment response in relapsing-remitting mul…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS [Phase 4]
Phase 4 clinical trial update for ELIOS investigating investigational biomarkers to track disease modification in active Relapsing Remitting…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Intermittent Hypoxia in Persons With Multiple Sclerosis [NA]
A clinical trial update indicates a study evaluating intermittent hypoxia in people with Multiple Sclerosis is currently recruiting.